Match!
Diane J. Stevenson
University of Nottingham
10Publications
3H-index
52Citations
Publications 10
Newest
#1Diane J. StevensonH-Index: 3
Last.Christopher J. HawkeyH-Index: 79
view all 10 authors...
Introduction The Helicobacter Eradication Aspirin Trial (HEAT) is a multicentre, double blind, randomised controlled trial investigating whether Helicobacter pylori eradication reduces the incidence of hospitalisation for peptic ulcer bleeding [1]. Participants are subjects aged over 60, taking low dose aspirin for at least four months at the time of recruitment; all participants were recruited from primary care. H. pylori positive participants were randomised to receive one week active trial tr...
#1Jennifer S. Dumbleton (University of Nottingham)H-Index: 1
#2Anthony J Avery (University of Nottingham)H-Index: 47
Last.Christopher J. Hawkey (University of Nottingham)H-Index: 79
view all 11 authors...
Background Clinical trials measuring the effect of an intervention on clinical outcomes are more influential than those investigating surrogate measures but are costly. We developed methods to reduce costs substantially by using existing data in primary care systems, to ask whether Helicobacter pylori eradication would reduce the incidence of hospitalisation for ulcer bleeding in aspirin users.
8 CitationsSource
#1Christopher J. Hawkey (University of Nottingham)H-Index: 79
#2I. Burnett (Novartis)H-Index: 1
Last.M. Brown (University of Nottingham)H-Index: 1
view all 11 authors...
Summary Background Diclofenac-potassium (diclofenac--K) 25 mg liquid capsule is absorbed more quickly than the tablet formulation. It offers potential for rapid pain relief, but may alter gastro-duodenal tolerability. Aim To evaluate the gastro-duodenal tolerance of diclofenac-K 25 mg liquid capsules vs. diclofenac-K 12.5 mg tablets, acetylsalicylic acid (ASA) 500 mg tablets and ibuprofen 200 mg liquid capsules. Methods In an endoscopist-blinded, randomised, parallel-group study, volunteers rece...
6 CitationsSource
#1Clare T. Atherton (University of Nottingham)H-Index: 5
#2John Jones (University of Nottingham)H-Index: 4
Last.Christopher J. Hawkey (University of Nottingham)H-Index: 79
view all 13 authors...
Abstract Background & Aims: Lumiracoxib is a structurally novel, acidic selective inhibitor of cyclooxygenase (COX)-2. We coordinated existing methodologies in a single study to evaluate potency, selectivity, and effect on the human gastrointestinal tract. Methods: Twenty four healthy subjects (aged 18–45 years, 12 female) received high dose lumiracoxib (800 mg every day), standard dose naproxen (500 mg twice a day), or placebo for 8 days in a double-blind randomized crossover study. At the star...
38 CitationsSource
#1Diane J. StevensonH-Index: 3
#2Mandy LawsonH-Index: 12
Last.Christopher J. HawkeyH-Index: 79
view all 5 authors...
Source
#1Clare T. AthertonH-Index: 5
Last.Christopher J. HawkeyH-Index: 79
view all 11 authors...
Source
Source
#1Shri PathmakanthanH-Index: 4
#2Chris K. F. LiH-Index: 5
Last.Christopher J. HawkeyH-Index: 79
view all 5 authors...
Source
#1Najam A. Sharif (University of Nottingham)H-Index: 2
#2Diane J. Stevenson (University of Nottingham)H-Index: 3
Last.John N. Hawthorne (University of Nottingham)H-Index: 17
view all 3 authors...
Source
1